Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Increases By 188.0%

Key Points

• Inventiva S.A. Sponsored ADR (NASDAQ:IVA) experienced a remarkable increase in short interest, rising by 188.0% in August from 10,000 to 28,800 shares.
• Analysts have issued positive ratings for Inventiva, with Piper Sandler and HC Wainwright providing "overweight" and "buy" ratings along with target prices of $26.00 and $20.00, respectively.
• Institutional investors hold 19.06% of Inventiva's stock, with Wealth Enhancement Advisory Services recently increasing its stake by 54.5% in the second quarter.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) was the target of a large growth in short interest in the month of August. As of August 15th, there was short interest totaling 28,800 shares, agrowthof188.0% from the July 31st total of 10,000 shares. Based on an average daily volume of 24,800 shares, the short-interest ratio is currently 1.2 days. Based on an average daily volume of 24,800 shares, the short-interest ratio is currently 1.2 days.

Institutional Trading of Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,715 shares of the company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IVA. Piper Sandler began coverage on shares of Inventiva in a research report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price on the stock. HC Wainwright started coverage on shares of Inventiva in a research report on Wednesday, September 3rd. They set a "buy" rating and a $20.00 target price on the stock. Finally, Guggenheim lifted their price objective on shares of Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $14.83.

Inventiva Stock Performance

NASDAQ:IVA remained flat at $5.37 during trading hours on Tuesday. 40,540 shares of the company's stock traded hands, compared to its average volume of 23,395. Inventiva has a 12 month low of $1.53 and a 12 month high of $6.50. The company's 50-day moving average is $3.95 and its 200 day moving average is $3.49.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.